Regression of soft drusen and drusenoid pigment epithelial detachment following intravitreal anti-vascular endothelial growth factor therapy.
Radhika
R
Krishnan
Jonathan
J
Lochhead
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007267:Injections; D000069579:Ranibizumab; D012074:Remission Induction; D012163:Retinal Detachment / Q000188:drug therapy; D015593:Retinal Drusen / Q000188:drug therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab